ImmunityBio's Strategic Expansion Fueled by Record Product Revenue

ImmunityBio reports explosive 700% revenue growth to $113M in 2025, driven by ANKTIVA. Global expansion and new FDA submissions set stage for 2026 commercialization.

ImmunityBio has reported a transformative year, with its 2025 financial performance demonstrating explosive growth. The company's product revenue surged to $113 million, marking a staggering 700 percent increase compared to the prior year. This momentum sets the stage for its next strategic phase: a comprehensive global commercialization effort, a plan detailed at the 38th Annual ROTH Conference commencing March 22, 2026.

Financial Performance and Core Product Strength

A key highlight of the company's fourth-quarter 2025 results was an earnings beat. ImmunityBio posted revenue of $38.28 million, surpassing the consensus estimate of $35.99 million. Furthermore, it reported a smaller loss per share than analysts had anticipated, at -$0.06 versus the projected -$0.11.

This financial acceleration is primarily attributed to the commercial success of ANKTIVA, the company's flagship product. Unit sales for ANKTIVA skyrocketed by 750 percent. A significant milestone for its U.S. market access was achieved in January 2025, when ANKTIVA received a permanent J-Code (J9028). This designation streamlines reimbursement processes with insurers, facilitating deeper commercial penetration.

Global Regulatory Momentum and Clinical Developments

ImmunityBio's international strategy is advancing rapidly. ANKTIVA has now gained regulatory approval in 33 countries across four major jurisdictions. The recent addition of Macau SAR on March 20, 2026, follows earlier approvals in Saudi Arabia and the European Union, reflecting a targeted approach to regions with high bladder cancer prevalence and limited access to advanced immunotherapies.

On the regulatory front, the company submitted a supplemental Biologics License Application (sBLA) to the U.S. FDA on March 9, 2026. This application seeks approval for ANKTIVA in combination with BCG for patients with papillary NMIBC and includes long-term efficacy data previously requested by the agency.

Concurrent clinical progress supports this regulatory push. The QUILT-2.005 study completed patient enrollment in February 2026. An interim analysis of 366 randomized patients revealed compelling results: 84 percent of patients in the combination arm exhibited a complete response at nine months, compared to 52 percent in the BCG-alone arm. A formal BLA submission for this specific indication is targeted for the fourth quarter of 2026.

Pipeline and Forward-Looking Strategy

Looking ahead to the remainder of 2026, market analysts project the ANKTIVA franchise to generate approximately $195 million in revenue. Beyond its lead asset, ImmunityBio has reported a manufacturing breakthrough in the large-scale production and cryopreservation of natural killer (NK) cells. This technical advancement underpins a broader development pipeline that includes candidates for non-small cell lung cancer and glioblastoma.

Following its presentation at the ROTH Conference, the company is scheduled to maintain its engagement with the investment community through appearances at several institutional events, including the Citizens Life Sciences Conference and the Jefferies Biotech on the Beach Summit.